Imran Mir A of Rani Therapeutics (NASDAQ: RANI) receives 123,600 stock options
Rhea-AI Filing Summary
Rani Therapeutics Holdings, Inc. director and ten percent owner Imran Mir A received a grant of options to acquire 123,600 shares of Class A Common Stock. The options have an exercise price of 0.9515 per share and expire on May 27, 2036.
These director stock options vest in full on the first anniversary of the grant date, subject to continuous service, or earlier upon the company’s next annual stockholder meeting or a Change in Control, also subject to continuous service. Following this grant, the filing shows 123,600 derivative securities held directly.
Positive
- None.
Negative
- None.
Insider Trade Summary
1 transaction reported
Mixed
1 txn
Insider
IMRAN MIR A
Role
Director, 10% Owner
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Director Stock Option (Right to Buy) | 123,600 | $0.00 | -- |
Holdings After Transaction:
Director Stock Option (Right to Buy) — 123,600 shares (Direct)
Footnotes (1)
- [object Object]
Key Figures
Option grant size: 123,600 options
Exercise price: 0.9515 per share
Expiration date: May 27, 2036
+1 more
4 metrics
Option grant size
123,600 options
Director stock option covering Class A Common Stock
Exercise price
0.9515 per share
Exercise price for the director stock option
Expiration date
May 27, 2036
Option expiration for director stock option grant
Post-grant derivative holdings
123,600 derivative securities
Total derivative securities following the transaction
Key Terms
Director Stock Option (Right to Buy), 2021 Equity Incentive Plan, Change in Control, Continuous Service
4 terms
Director Stock Option (Right to Buy) financial
"security_title: "Director Stock Option (Right to Buy)""
2021 Equity Incentive Plan financial
"defined in the Company's 2021 Equity Incentive Plan (the "2021 Plan")"
Change in Control financial
"upon the occurrence of either of the following events: the Company's next annual stockholder meeting or a Change in Control"
A "change in control" occurs when the ownership or management of a company shifts significantly, such as through a merger, acquisition, or sale of a large part of its assets. This change can impact how the company is run and may influence its future direction. For investors, it matters because it can affect the company's stability, strategy, and value, often signaling potential changes in investment risk or opportunity.
Continuous Service financial
"subject to the Reporting Person's Continuous Service through such vesting date"
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What did Imran Mir A report in this Rani Therapeutics (RANI) Form 4?
Imran Mir A reported receiving a stock option grant for 123,600 shares. These options allow him to buy Rani Therapeutics Class A Common Stock at an exercise price of 0.9515 per share, reflecting a compensation-related award rather than an open-market purchase or sale.
What is the exercise price and expiration date of the RANI options granted?
The options have an exercise price of 0.9515 per share and expire on May 27, 2036. This means Imran Mir A can, once vested, buy shares at 0.9515 any time before the May 27, 2036 expiration date, subject to plan terms.
When do Imran Mir A’s Rani Therapeutics (RANI) options vest?
The options vest in full on the first anniversary of the grant date. Vesting also can occur earlier if Rani Therapeutics holds its next annual stockholder meeting or experiences a Change in Control, provided Imran Mir A maintains continuous service through the relevant date.
How many Rani Therapeutics (RANI) derivative securities does Imran Mir A hold after this grant?
After the grant, the filing shows 123,600 derivative securities held directly. These represent the stock options granted in this transaction, each tied to one share of Class A Common Stock, contingent on vesting and future exercise decisions.